ALX Oncology
ALXO
86 hedge funds and large institutions have $161M invested in ALX Oncology in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 25 reducing their positions, and 12 closing their positions.
7,900% more call options, than puts
Call options by funds: $80K | Put options by funds: $1K
20% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 25
0% more funds holding
Funds holding: 86 → 86 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
1.83% less ownership
Funds ownership: 89.19% → 87.37% (-1.8%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
61% less capital invested
Capital invested by funds: $410M → $161M (-$248M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$7.51M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$769K |
| 3 |
HF
HRT Financial
New York
|
+$625K |
| 4 |
Squarepoint
New York
|
+$479K |
| 5 |
Two Sigma Investments
New York
|
+$472K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$6.44M |
| 2 |
PC
Pier Capital
Stamford,
Connecticut
|
-$3.06M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.95M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$1.8M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.35M |
ALXO Hedge Fund Activity: Q1 2023 in Review
86 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q1 2023, worth a combined $161M — down 61% from $410M a quarter earlier.
Fund positioning in ALXO was balanced in Q1 2023: 12 funds opened new positions, 12 closed out, 30 added to existing stakes and 25 trimmed.
The largest buyer was Braidwell, adding an estimated $7.51M. The largest seller was Logos Global Management, cutting an estimated $6.44M.
- 86 institutional investors held ALX Oncology (ALXO) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $161M of ALX Oncology stock for Q1 2023, down 61% quarter-over-quarter.
- 12 funds opened new ALX Oncology positions in Q1 2023 and 12 closed out, a net change of 0 holders.
- The largest ALX Oncology buyer in Q1 2023 was Braidwell, an estimated $7.51M added.
- The largest ALX Oncology seller in Q1 2023 was Logos Global Management, an estimated $6.44M sold.
Based on aggregated 13F filings for Q1 2023.